Provided By GlobeNewswire
Last update: Mar 4, 2025
Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results
Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023.
Read more at globenewswire.comNASDAQ:DXR (10/17/2025, 8:07:29 PM)
12.9456
-0.05 (-0.42%)
Find more stocks in the Stock Screener